Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Not all antidepressants are created equal — at least when it comes to keeping depression at bay long-term. A sweeping review of 115 clinical trials found that Lexapro, Cymbalta, and Valdoxan were more effective than Prozac at sustaining symptom improvement. That said, researchers caution the findings aren't definitive, and no single antidepressant can be crowned the universal best.
Not all antidepressants are created equal — at least when it comes to keeping depression at bay long-term. A major review published in The Lancet Psychiatry analyzed 115 randomized controlled trials involving more than 30,000 people and found that escitalopram (Lexapro), duloxetine (Cymbalta), and agomelatine (Valdoxan) were more likely to sustain symptom improvement compared to fluoxetine (Prozac). Patients on Lexapro and Cymbalta were also less likely to drop out of trials, suggesting better tolerability.
Before anyone rushes to switch medications, researchers urge caution. More than half of the studies in the main analysis carried a high risk of bias, and most trials only followed participants for around six months — far shorter than the average four years people actually take antidepressants. The findings reflect group-level averages and can't predict what will work best for any individual.
Key Takeaways:
Why it matters: With millions of people on long-term antidepressant therapy, understanding which medications sustain benefits over time is critical. These findings offer a useful — if imperfect — signal for clinicians, while reinforcing that antidepressant selection should remain a personalized, shared decision between patient and provider.